MA50156A - Variants d'anticorps - Google Patents

Variants d'anticorps

Info

Publication number
MA50156A
MA50156A MA050156A MA50156A MA50156A MA 50156 A MA50156 A MA 50156A MA 050156 A MA050156 A MA 050156A MA 50156 A MA50156 A MA 50156A MA 50156 A MA50156 A MA 50156A
Authority
MA
Morocco
Prior art keywords
antibody variants
variants
antibody
Prior art date
Application number
MA050156A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA50156A publication Critical patent/MA50156A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA050156A 2017-09-19 2018-09-11 Variants d'anticorps MA50156A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17191989.7A EP3456738B1 (fr) 2017-09-19 2017-09-19 Variantes d'anticorps

Publications (1)

Publication Number Publication Date
MA50156A true MA50156A (fr) 2020-07-29

Family

ID=59923275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050156A MA50156A (fr) 2017-09-19 2018-09-11 Variants d'anticorps

Country Status (23)

Country Link
US (2) US11999781B2 (fr)
EP (3) EP3456738B1 (fr)
JP (2) JP7240385B2 (fr)
KR (1) KR20200053514A (fr)
CN (1) CN111094343B (fr)
AR (1) AR113303A1 (fr)
AU (1) AU2018337495B2 (fr)
BR (1) BR112020005482A2 (fr)
CA (1) CA3075959A1 (fr)
CL (1) CL2020000721A1 (fr)
CO (1) CO2020003260A2 (fr)
CR (2) CR20210205A (fr)
EA (1) EA202090617A1 (fr)
GE (1) GEP20237484B (fr)
IL (1) IL273351A (fr)
JO (1) JOP20200063A1 (fr)
MA (1) MA50156A (fr)
MX (1) MX2020002989A (fr)
PH (1) PH12020500473A1 (fr)
SA (1) SA520411559B1 (fr)
SG (1) SG11202002220TA (fr)
TW (1) TW201915021A (fr)
WO (1) WO2019057564A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7464389B2 (ja) 2016-08-02 2024-04-09 ビステラ， インコーポレイテッド 操作されたポリペプチドおよびその使用
WO2020114616A1 (fr) 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202008722QA (en) * 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
AU2005323025A1 (en) 2004-12-31 2006-07-13 Biogen Idec Ma Inc. Polypeptides that bind BR3 and uses thereof
EP3825329A1 (fr) * 2007-12-26 2021-05-26 Xencor, Inc. Variants fc avec liaison altérée à fcrn
PL2307457T5 (pl) * 2008-06-25 2022-12-27 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące tnf
EP3122777B1 (fr) 2014-03-26 2020-12-23 Cell Medica Switzerland AG Éléments de liaison dirigés contre tnf alpha
BR112016023948A2 (pt) * 2014-04-16 2018-01-30 Ucb Biopharma Sprl proteínas fc multiméricas
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CR20180445A (es) * 2016-03-14 2019-02-08 Univ Oslo Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
SI3219726T1 (sl) * 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti

Also Published As

Publication number Publication date
CR20210205A (es) 2021-07-27
CL2020000721A1 (es) 2020-08-07
JOP20200063A1 (ar) 2020-03-17
CO2020003260A2 (es) 2020-04-13
JP2023036885A (ja) 2023-03-14
CN111094343A (zh) 2020-05-01
GEP20237484B (en) 2023-03-27
US20200216527A1 (en) 2020-07-09
WO2019057564A1 (fr) 2019-03-28
CR20200132A (es) 2020-07-24
JP7402304B2 (ja) 2023-12-20
MX2020002989A (es) 2020-07-22
EP4424707A2 (fr) 2024-09-04
JP7240385B2 (ja) 2023-03-15
CN111094343B (zh) 2024-09-20
EP3456738C0 (fr) 2024-07-17
US20240343793A1 (en) 2024-10-17
EP3684807A1 (fr) 2020-07-29
IL273351A (en) 2020-05-31
KR20200053514A (ko) 2020-05-18
TW201915021A (zh) 2019-04-16
AR113303A1 (es) 2020-04-08
AU2018337495B2 (en) 2024-10-17
SA520411559B1 (ar) 2024-03-19
AU2018337495A1 (en) 2020-04-09
EP3456738A1 (fr) 2019-03-20
US11999781B2 (en) 2024-06-04
JP2020534307A (ja) 2020-11-26
PH12020500473A1 (en) 2021-01-25
EA202090617A1 (ru) 2020-07-27
BR112020005482A2 (pt) 2020-09-29
SG11202002220TA (en) 2020-04-29
CA3075959A1 (fr) 2019-03-28
EP3456738B1 (fr) 2024-07-17

Similar Documents

Publication Publication Date Title
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA49043A (fr) Formulation stable d'anticorps
MA53434A (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
MA52884A (fr) Anticorps anti-il-11
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA46041A (fr) Anticorps anti-tim -3
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA52212A (fr) Anticorps multivalent
MA49749A (fr) Anticorps anti-cd137
MA45231A (fr) Anticorps anti-ige
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA44236A (fr) Anticorps anti-tgfbêta 2
MA52152A (fr) Anticorps
MA44054A (fr) Plateforme d'anticorps bispécifique
MA52366A (fr) Anticorps anti-tl1a optimisés
MA51134A (fr) Anticorps anti-alpha-synucléine
MA42843A (fr) Anticorps anti-cd115
MA54052A (fr) Formulation d'anticorps
MA54139A (fr) Formulation d'anticorps